What did SourceBio International pay for LDPath Limited?

SourceBio International acquired LDPath Limited for $24.2M in 2022 (46.3x EBITDA), equivalent to 4.00x revenue. Target revenue was approximately $6.0M. Target EBITDA was approximately $0.5M.

What does LDPath Limited do?

LDPath Limited is a healthcare it business.

What multiple did SourceBio International pay for LDPath Limited?

46.3x EBITDA and 4.00x revenue, based on disclosed deal value of $24.2M and disclosed financials.

M&A TRANSACTION · 2022

LDPath Limited acquired by SourceBio International

$24.2M· 46.3x EBITDA· 4.00x revenue

Target

LDPath Limited

Acquirer

SourceBio International

Strategic buyer

Disclosed financials at time of acquisition

Revenue

$6.0M

EBITDA

$0.5M

Deal Value

$24.2M

EV/EBITDA

46.3x

Context

This $24.2M acquisition of LDPath Limited by SourceBio International sits in the healthcare it sub-vertical. The 46.3x EBITDA multiple paid in 2022 can be compared against the population median for healthcare it transactions of similar size on our Healthcare It valuation hub. SourceBio International is acquiring as a strategic buyer; see how strategic acquirers typically price healthcare it businesses on our Healthcare It strategic buyer-pool page.

Source

Data sourced from Press releases. All figures reflect disclosed values at the time of the acquisition; no estimated or imputed data. Methodology

Value your own healthcare it

Get an instant valuation range for your business. Backed by 25,592 real M&A transactions.

Compare your business to the LDPath Limited acquisition.

Citation: ExitValue.ai. (2022). LDPath Limited acquired by SourceBio International. https://exitvalue.ai/deals/ldpath-limited-acquired-by-sourcebio-international-hc-2022-0072